This inventor holds 1 USPTO granted patent and 4 published patent applications and 1 EPO patent. Top assignee: Agency for Science, Technology and Research. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: Farah Tasnim: Innovator in Stem Cell Research
Introduction
Farah Tasnim is a prominent inventor based in Singapore, known for her groundbreaking work in stem cell research. She has made significant contributions to the field, particularly in the differentiation of hepatocyte-like cells from stem cells. Her innovative methods have the potential to advance medical research and drug screening.
Latest Patents
Farah Tasnim holds a patent for the differentiation of hepatocyte-like cells from stem cells. The patent discloses methods that involve subjecting definitive endoderm to at least one epigenetic modulator to obtain hepatoblasts. Following this, the hepatoblasts are subjected to at least one stem cell differentiation pathway inhibitor to obtain hepatocyte-like cells. Notably, the methods do not comprise the use of a growth factor. In preferred embodiments, the epigenetic modulator may include sodium butyrate and/or DMSO, while the stem cell differentiation pathway inhibitor may include SB431542 and/or DMSO. The patent also covers the hepatocyte-like cells obtained from these methods and their applications in drug screening.
Career Highlights
Farah Tasnim is affiliated with the Agency for Science, Technology and Research, where she continues to push the boundaries of scientific knowledge. Her work has garnered attention for its innovative approach to stem cell differentiation, which could have far-reaching implications in regenerative medicine.
Collaborations
Farah collaborates with esteemed colleagues such as Yi-chin Toh and Hanry Yu, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Farah Tasnim's contributions to stem cell research exemplify the spirit of innovation in the scientific community. Her patented methods for differentiating hepatocyte-like cells from stem cells represent a significant advancement in the field, with promising applications in drug screening and beyond.